Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2011-06-21
2011-06-21
Li, Bao (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093100, C424S093300, C424S215100, C435S320100
Reexamination Certificate
active
07964187
ABSTRACT:
The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.
REFERENCES:
patent: 6100243 (2000-08-01), Frisch
patent: 6136307 (2000-10-01), Lee et al.
patent: 6565831 (2003-05-01), Coffey et al.
patent: 7264798 (2007-09-01), Coffey et al.
patent: 7608257 (2009-10-01), Coffey et al.
patent: 2283280 (1999-02-01), None
patent: 2360833 (2000-08-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/25627 (1994-11-01), None
patent: WO 96/07322 (1996-03-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 00/50051 (2000-08-01), None
Andreansky, S.A. et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors”, Proc. Natl. Acad. Sci. 93(21):11313-11318 (1996).
Baldari, C. T. et al “Interluekin-2 promoter activation in T-cells expressing activated Ha-ras”, J. Biological Chemistry 267(7): 4289-4291 (1992).
Bar-Eli, N. et al., “Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells”, J. Cancer Res. Clin. Oncol. 122: 409-415 (1996).
Bergmann, M. et al., “A Genetically Engineered Influenza A Virus with ras-Dependent Oncolytic Properties”, Cancer Res. 61:8188-8193 (2001).
Bischoff Jr. et al. “An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells”, Science 274(5286):373-6 (1996).
Blagoslelonny, M.V. et al., “in vitro Evaluation of ap53-Expressing Adenovirus as an Anti-Cancer Drug”, Int. J. Cancer 67(3):386-392 (1996).
Bona et al., Chapter II in Textbook of Immunology, edited by Bone et al., Hardwood Academic Publishers pp. 331-334 (1996).
Borst et al., “A Family of Drug Transporters: the Multidrug Resistance Associated Proteins”, J. Natl. Cancer Inst. 92(16): 1295-1302 (2000).
Bryson, J.S. and D.C. Cox, “Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia”, Cancer Immunol. Immunother. 26: 132-138 (1988).
Chandran and Nibert, “Protease Cleavage of Reovirus Capsid Protein 1L1/1L1C is Blocked by Alkyl Sulfate Detergents, Yielding a New Type of Infectious Subvirion Particle”, J. of Virology 72(1):467-75 (1998).
Chang et al., “Rescue of Vaccinia Virus Lacking the E3L Gene by Mutants of E3L”, J. Virol. 69:6605-6608 (1995).
Chang et al., “The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase”, Proc. Natl. Acad. Sci. 89:4825-4829 (1992).
Chang et al., “Identification of a Conserved Motif that is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNA”, Virol. 194:537-547 (1993).
Clarke at al., “Reovirus-induced apoptosi.s is mediated by TRAIL”, Journal of Virology, 2000, vol. 74, No. 17, pp. 8135-8139.
Coffey, M.C. et al., “Reovirus Therapy of Tumors with Activated Ras Pathway”, Science 282: 1332-1334 (1998).
DeVita, Jr., “The Relationship Between Tumor Mass and Resistance to Chemotherapy. Implications for Surgical Adjuvant Treatment of Cancer”, Cancer 51:1209-1220 (1983).
Duncan et al., “Conformational and Functional Analysis of the C-Terminal Globular Head of the Reovirus Cell Attachment Protein”, Virology 182(2):810-9 (1991).
Farassati, F. et al., “Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1”, Nat. Cell Biol. 3(8):745-750 (2001).
Fuertes et al., Current Medicine Chemistry 10:257-66 (2003).
Fueyo, J. et al., “A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect in Vivo”, Oncogene 19(1):2-12 (2000).
Fujiwara et al. , “Induction of chemotherapy in human lung cancer cells in vivo by Adenovirue-mediated transfer of the wild-type p53 gene”, Cancer Research, 1994, vol. 54, pp. 2287-2291.
Fujiwara, T. et al., Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-mediated Transfer of the Wild-Type p53 Gene, Cancer Research 54:2298-2291 (1994).
Grant et al., “Overexpression of Multidrug Resistance-Associated Protein (MRP) Increases Resistance to Natural Product Drugs”, Cancer Res. 54:357-361 (1994).
Heise, C. et al., “Replication-selective adenoviruses as oncolytic agents”, J. Clin. Invest. 105(7):847-51 (2000).
Heise, C. et al., Efficacy with a Replication-selective Adenoviurs Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration, Clinical Cancer Research 6:4908-4914 (2000).
Hirasawa et al., Reovirus therapy of metastatic cancer models in immune-competent mice on the website of Oncolytics Biotech Inc. (http://www.oncolyticsbiotech.com/022801p1.html) (2001).
Hirasawa, K. et al., Systemic Reovirus Therapy of Metastatic Cancer Models in Immune-competent Mice, Cancer Res. 63(2):348-53 (2003).
Kawagishi-Kobayashi, M. et al., “Regulation of the Protein Kinase PKR by the Vaccinia Virus Pseudosubstrate Inhibitor K3L is Dependent on Residues Conserved between the K3L Protein and the PKR Substrate eIF2a.”, Mol. Cell. Riol. 17 :4146-4158 (1997).
Kim, D., Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer, Oncogene 19:6660-6669 (2000).
Khuri et al., “A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer”, Nat Med 6(8):862-3 (2000).
Liu, Oncogene expression in adriamycin and platinum resistant cell lines, Zhonghua Yi Xue Za Zhi 73(9):552-4, 576 (1993).
Mah et al., “The N-Terminal Quarter of Reovirus Cell Attachment Protein σ1 Possesses Intrinsic Virion-Anchoring Function”, Virology 179(1):95-103 (1990).
Mercer University, Mercer Univeristy Homepage 1996 pp. 1-2.
Nemunaitis, J., “Oncolytic viruses”, Invest. New Drugs 17:375-386 (1999).
Orr et al., Oncogen 22:7280-95 (2003).
Pastan and Gottesman, “Multidrug Resistance”, Annu. Rev. Med. 42:277-286 (1991).
Prigent et al., Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the ras-she-grb2 pathway, Biologic. Chemistr. 271:25635-45 (1996).
Rayter, S. I. et al., “p21ras mediates control of IL-2 gene promoter function in T cell activation”, EMBO Journal 11(12): 4549-4556 (1992).
Reichard, K.W. et al., “Newcastle Disease Virus Selectively Kills Human Tumor Cells”, J. of Surgical Research 52:448-453 (1992).
Romano et al., “Inhibition of Double-Stranded RNA-Dependent Protein Kinase PKR by Vaccinia Virus E3: Role of Complex Formation and the E3 N-Terminal Domain”, Mol. Cell. Rio. 18(12):7304-7316 (1998).
Sansing et al., “Evaluation of time and dose in treating mammary adenocarcinoma with immunostimulants”, Cancer Immunology, Immunotherapy, 1977, vol. 2, No. 1, pp. 63-68.
Sharp et al., “The Vaccinia Virus E3L Gene Product Interacts with both the Regulatory and the Substrate Binding Regions of PKR: Implications for PKR Autoregulation”, Virology 250:302-315 (1998).
Smith, R.E. et al., “Polypeptide Components of Virions, Top Component and Cores of Reovirus Type 3”, Virology, 39:791-800 (1969).
Smith and Chiocca, Oncolytic viruses as novel anticancer agents: turning one scourge against another, Exp. Opin. Invest. Drugs 9:311-27 (2000).
Steele, T. A. and Cox, D. C., “Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporin”, Cancer Biotherapy 10(4): 307-315 (1995).
Stojdl, D. F. et al., “Exploiting tumor-specific defects in the interferon pathway
Coffey Matthew C.
Thompson Bradley G.
Li Bao
McKeon Meunier Carlin & Curfman LLC
Oncolytics Biotech Inc.
LandOfFree
Sensitization of chemotherapeutic agent resistant neoplastic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sensitization of chemotherapeutic agent resistant neoplastic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sensitization of chemotherapeutic agent resistant neoplastic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2697308